RT Journal Article
SR Electronic
T1 Prevalence of SARS-CoV-2 antibodies in Denmark 2020: results from nationwide, population-based sero-epidemiological surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21254703
DO 10.1101/2021.04.07.21254703
A1 Espenhain, Laura
A1 Tribler, Siri
A1 Jørgensen, Charlotte Sværke
A1 Holm Hansen, Christian
A1 Wolff Sönksen, Ute
A1 Ethelberg, Steen
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2021.04.07.21254703.abstract
AB Background Seroprevalence studies have proven an important tool to monitor the progression of the coronavirus disease 2019 (COVID-19) epidemic. We present results of consecutive population-based seroprevalence surveys performed in Denmark in 2020.Methods Invitation letters including a questionnaire covering symptoms were sent to representatively drawn samples of the population in spring, late summer and autumn/winter of 2020. Blood samples from participants taken at public test-centers were analyzed for total Ig and seroprevalence estimates per population segment calculated and compared to other surveillance parameters.Results From 34,081 participating individuals (response rate 33%), we obtained seroprevalence estimates increasing from 1.1% (95%CI: 0.7%–1.7) in May to 4.0 % (95%CI: 3.4%–4.7%) in December 2020. By December 2020, 1.5% of the population 12 years and older had tested positive by PCR. Seroprevalence estimates were roughly 3 times higher in those aged 12-29 compared to 65+ and higher in metropolitan municipalities. Among seropositives, loss of taste/smell were the more specific symptoms, 32%-56% did not report any symptoms. In half of seroconverted families, we did not see evidence of transmission between generations. Infected individuals in older age groups were hospitalized several fold more often than in younger.Conclusions Seroprevalence increased during 2020; younger age groups were primarily infected in the autumn/winter surge. Approximately half were asymptomatically infected. Denmark has a high per capita test rate; roughly two undiagnosed infections of COVID-19 were estimated to occur for each diagnosed case. The epidemic appears to have progressed relatively modestly during 2020 in Denmark.summary We describe population-based COVID-19 seroprevalence surveys performed in Denmark in 2020. The seroprevalence increased during the year, particularly in adolescents and young adults, but was overall low. Roughly two undiagnosed cases per PCR-confirmed case were detected by December 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://files.ssi.dk/Ekspertudvalgsrapport%20vedr%20stikprvedesign07052020revideret%2013052020bg20 Funding StatementWe did not receive external funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DSS was performed as a national disease surveillance project, registered with the Danish Data Protection Agency and approved regarding legal, ethical and cyber-security issues by the SSI Compliance department in conjunction with the Danish governmental law firm. Participation in the survey was voluntary and invitees received information about the selection procedure, risks associated with participation, data security issues, their legal rights, including the right to withdraw from the study, and the use of their data and results in the letter of invitation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available